Search clinical trials for: Cetuximab (SCCHN)

Total 3052 results

Qilu Hospital of Shandong University

Recruiting

Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer

Colon Cancer

China
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Glioma | Melanoma | Thyroid Cancer | Non-Small-Cell Lung Cancer

United States, Canada, Israel
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Head and Neck Cancer

Head and Neck Cancer
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

EBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditions

United States
Sun Yat-sen University

Active, not recruiting

Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer (C-CLASSIC)

Colorectal Cancer

China
Enzon Pharmaceuticals, Inc.

Unknown

A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

United States, Canada, Israel, Netherlands, United Kingdom
Sun Yat-sen University

Recruiting

Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer (CEIL)

Metastatic Colorectal Cancer

China
University of California, Davis
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397

Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Johns Hopkins University; M.D. Anderson Cancer Center; University of Colorado... and other collaborators

Completed

External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas

Brain Cancer

United States, Canada
Translational Genomics Research Institute
Eli Lilly and Company

Withdrawn

Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

Metastatic Colorectal Cancer

United States
University of Medicine and Dentistry of New Jersey
Bristol-Myers Squibb; Rutgers Cancer Institute of New Jersey

Terminated

First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients

Colorectal Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer

Lung Cancer

United States
Institute of Oncology Ljubljana

Unknown

Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer (XERT)

Rectal Cancer

Slovenia
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
Associazione Volontari Pazienti Oncologici
Mario Negri Institute for Pharmacological Research

Completed

Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (H&N07)

Head and Neck Squamous Cell Carcinoma

Italy
University Medical Center Groningen

Recruiting

MSOT Using Cetuximab-800CW for Detection of Cervical Lymph Node Metastases (OPUS)

Oral Cancer | Lymph Node Metastases

Netherlands
Bristol-Myers Squibb

Active, not recruiting

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Canada, United States, Mexico
Ahmed A. H. Abdellatif

Unknown

Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer

Colon Cancer | Colo-rectal Cancer

Egypt, Saudi Arabia
RenJi Hospital

Active, not recruiting

Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer

Rectal Cancer Stage III

China
Hadassah Medical Organization

Unknown

Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma

Breast Neoplasms

Israel
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Multiple Myeloma, Neoplasms

United States, China, France, Spain, United Kingdom, Germany
Gustave Roussy, Cancer Campus, Grand Paris
Ministry of Health, France

Completed

Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract (JANORL2)

Squamous Cell Carcinoma

France
National University Hospital, Singapore

Unknown

A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab

Rectal Cancer

Singapore
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia

United States
Fudan University

Recruiting

c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI

Colorectal Cancer

China
Tizona Therapeutics, Inc

Active, not recruiting

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Cancer

United States
Peking University
Merck Sharp & Dohme LLC

Completed

A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer (EXTRA)

Gastric Cancer

China
UNICANCER

Completed

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

France
Boehringer Ingelheim

Completed

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Neoplasms

France, Spain
Pfizer

Completed

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Rheumatoid Arthritis

United States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
Eli Lilly and Company

Completed

Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

Cancer | Refractory Solid Tumor

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Head and Neck Cancer

United States, Canada
Huazhong University of Science and Technology
The First Affiliated Hospital of Nanchang University; Henan Cancer Hospital; Hunan...

Unknown

A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer

Colorectal Neoplasms

China
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

Lung Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center
Oncology/Hematology West

Completed

Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
Mabion SA
Parexel

Withdrawn

MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis (MABRIDGE)

Rheumatoid Arthritis
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Recurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 and other conditions

United States
Gruppo Oncologico del Nord-Ovest

Unknown

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (CRICKET)

Metastatic Colorectal Cancer

Italy
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

Colorectal Cancer

United States, Australia, Austria, Belgium, Czech Republic, Finland, France, Germany, Hong Kong, Italy, Netherlands, Norway, Portugal, Slovakia, Sweden, Switzerland, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
Abramson Cancer Center of the University of Pennsylvania
Bristol-Myers Squibb; Roche Pharma AG

Terminated

Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma

Rectal Cancer
GERCOR - Multidisciplinary Oncology Cooperative...

Terminated

Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study (REGAIN)

Colorectal Cancer Metastatic

France
University of California, Davis
National Cancer Institute (NCI)

Completed

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
The Methodist Hospital Research Institute
Bristol-Myers Squibb; Eli Lilly and Company

Terminated

Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy

Prostatic Neoplasms

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
Shanghai Institute Of Biological Products

Not yet recruiting

Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
Swiss Group for Clinical Cancer Research

Completed

Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer

Prostate Cancer

Switzerland

Search clinical trials for: Cetuximab (SCCHN)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations